TW199144B - - Google Patents

Download PDF

Info

Publication number
TW199144B
TW199144B TW080106710A TW80106710A TW199144B TW 199144 B TW199144 B TW 199144B TW 080106710 A TW080106710 A TW 080106710A TW 80106710 A TW80106710 A TW 80106710A TW 199144 B TW199144 B TW 199144B
Authority
TW
Taiwan
Prior art keywords
compound
phenyl
formula
diseases
ministry
Prior art date
Application number
TW080106710A
Other languages
English (en)
Chinese (zh)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of TW199144B publication Critical patent/TW199144B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Electroluminescent Light Sources (AREA)
  • Eye Examination Apparatus (AREA)
TW080106710A 1990-09-28 1991-08-23 TW199144B (index.php)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59042390A 1990-09-28 1990-09-28

Publications (1)

Publication Number Publication Date
TW199144B true TW199144B (index.php) 1993-02-01

Family

ID=24362216

Family Applications (1)

Application Number Title Priority Date Filing Date
TW080106710A TW199144B (index.php) 1990-09-28 1991-08-23

Country Status (22)

Country Link
EP (1) EP0550635B1 (index.php)
JP (1) JPH0772175B2 (index.php)
CN (1) CN1060285A (index.php)
AT (1) ATE121389T1 (index.php)
AU (1) AU651145B2 (index.php)
BR (1) BR9106905A (index.php)
CA (1) CA2089736A1 (index.php)
CZ (1) CZ387492A3 (index.php)
DE (1) DE69109125T2 (index.php)
DK (1) DK0550635T3 (index.php)
ES (1) ES2071334T3 (index.php)
FI (1) FI931370A7 (index.php)
HU (1) HUT68667A (index.php)
IE (1) IE66042B1 (index.php)
IL (1) IL99525A0 (index.php)
MX (1) MX9101274A (index.php)
NO (1) NO931151D0 (index.php)
PT (1) PT99064A (index.php)
TW (1) TW199144B (index.php)
WO (1) WO1992006079A1 (index.php)
YU (1) YU159291A (index.php)
ZA (1) ZA917744B (index.php)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
SK282203B6 (sk) * 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
TW202432B (index.php) * 1991-06-21 1993-03-21 Pfizer
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
DE69231395T3 (de) * 1991-09-20 2005-07-21 Glaxo Group Ltd., Greenford Neue medizinische Indikation für Tachykinin-Antagonisten
HUT70741A (en) * 1991-11-12 1995-10-30 Pfizer Acyclic ethylenediamine derivatives as substance p receptor antagonists
DE69331190T2 (de) * 1992-05-18 2002-04-18 Pfizer Inc., New York Überbrückte azabicyclische derivate als substanz p antagonisten
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859A (en) * 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US5688804A (en) * 1992-08-04 1997-11-18 Pfizer Inc. 3-Benzylamino-2-phenyl-piperidine derivatives as substance P receptor antagonists
GB9216911D0 (en) * 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
EP1114823A3 (en) * 1992-08-19 2001-07-18 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
AU5169693A (en) * 1992-12-10 1994-07-04 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US5854262A (en) * 1993-10-07 1998-12-29 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
FR2725900B1 (fr) * 1994-10-21 1997-07-18 Sanofi Sa Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
AU6144098A (en) * 1997-02-14 1998-09-08 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
CA2251580A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amides as npy5 receptor antagonists
CN1414953A (zh) 1999-11-03 2003-04-30 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和5－羟色胺重摄取的用途
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
US7119207B2 (en) 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
AU2001246761A1 (en) * 2000-04-10 2001-10-23 Pfizer Products Inc. Benzoamide piperidine compounds as substance P antagonists
BR0112350A (pt) 2000-07-11 2003-06-24 Albany Molecular Res Inc Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico
CA2424292A1 (en) * 2000-10-10 2002-04-18 Calyx Therapeutics, Inc. Tricyclic compounds and uses thereof
CA2573271C (en) 2004-07-15 2015-10-06 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
DE102005027168A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
NZ565111A (en) 2005-07-15 2011-10-28 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
CN101277960A (zh) 2005-09-29 2008-10-01 默克公司 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0617867D0 (en) * 2006-09-11 2006-10-18 Glaxo Group Ltd Chemical compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EA200970706A1 (ru) 2007-01-24 2010-02-26 Глэксо Груп Лимитед Новые фармацевтические композиции
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
GB0716573D0 (en) * 2007-08-24 2007-10-03 Glaxo Group Ltd Chemical compounds
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
GB0804326D0 (en) * 2008-03-07 2008-04-16 Glaxo Group Ltd Novel compounds
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
MX2011011900A (es) 2009-05-12 2012-01-20 Squibb Bristol Myers Co Formas cristalinas de (s)-7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4 -(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y usos de las misma.
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
JP5764553B2 (ja) 2009-05-12 2015-08-19 アルバニー モレキュラー リサーチ， インコーポレイテッド ７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンおよびその使用
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US20140045832A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Insulin-Like Growth Factor-1 Receptor Inhibitors
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CN104610146A (zh) * 2015-01-23 2015-05-13 常州大学 一种3-氮杂二环[5,1,0]-7-醛及合成方法
CN105330588B (zh) * 2015-10-16 2017-09-26 辽宁中医药大学 马齿苋中生物碱Oleracone及其提取分离方法
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
CN113121427B (zh) * 2021-03-19 2022-04-01 广东工业大学 一种喹啉类衍生物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452026A (en) * 1966-03-15 1969-06-24 Bristol Myers Co Substituted 1,2,3,4-tetrahydroquinolines
FR1555552A (index.php) * 1967-07-05 1969-01-31
US4198415A (en) * 1979-01-22 1980-04-15 Eli Lilly And Company Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists

Also Published As

Publication number Publication date
ZA917744B (en) 1993-03-29
MX9101274A (es) 1992-05-04
JPH0772175B2 (ja) 1995-08-02
WO1992006079A1 (en) 1992-04-16
YU159291A (sh) 1994-01-20
AU651145B2 (en) 1994-07-14
ES2071334T3 (es) 1995-06-16
DE69109125T2 (de) 1995-09-28
EP0550635A1 (en) 1993-07-14
NO931151L (no) 1993-03-26
IE913396A1 (en) 1992-04-08
CN1060285A (zh) 1992-04-15
PT99064A (pt) 1992-08-31
ATE121389T1 (de) 1995-05-15
FI931370L (fi) 1993-03-26
AU8746391A (en) 1992-04-28
BR9106905A (pt) 1993-08-17
FI931370A0 (fi) 1993-03-26
DK0550635T3 (da) 1995-09-04
DE69109125D1 (de) 1995-05-24
CA2089736A1 (en) 1992-03-29
NO931151D0 (no) 1993-03-26
IE66042B1 (en) 1995-12-13
HUT68667A (en) 1995-07-28
CZ387492A3 (en) 1994-02-16
HU9300898D0 (en) 1993-06-28
EP0550635B1 (en) 1995-04-19
JPH06501267A (ja) 1994-02-10
FI931370A7 (fi) 1993-03-26
IL99525A0 (en) 1992-08-18

Similar Documents

Publication Publication Date Title
TW199144B (index.php)
EP0613458B1 (en) Acyclic ethylenediamine derivatives as substance p receptor antagonists
RU2351588C2 (ru) Производные n-фенил(пиперидин-2-ил)метил-бензамида и их применение в терапии
EP0591040B1 (fr) Amides basiques quaternaires comme antagonistes des tachykinines
TW201301B (index.php)
JP3242980B2 (ja) ポリサイクリックアミン化合物、そのエナンショマー、その製造方法、およびこれらを含有する薬剤組成物
CS1091A3 (en) 3-aminopiperidine derivatives and method of their production
JPH03176469A (ja) イソインドロン誘導体
JP5663657B2 (ja) １−［（４−ヒドロキシピペリジン−４−イル）メチル］ピリジン−２（１ｈ）−オン誘導体、その調製方法およびその使用
SK119795A3 (en) Indole derivatives as 5-ht1a and/or 5-ht2 ligands
RS20060316A (sr) Derivati n-/heteroaril(piperidin-2-il)metil/benzamida, postupak za njihovo dobijanje i njihova terapeutska primena
TW200817406A (en) Imidazole amines as inhibitors of β-secretase
AU603004B2 (en) 1-((2-pyrimidinyl)aminoalkyl)piperidines, their preparation and their application in therapy
TW472054B (en) Azetidines
JP2935541B2 (ja) 縮合複素環化合物
JPS62192358A (ja) 置換されたテトラヒドロ―３―ピリジンカルボン酸誘導体およびその製造方法
EP0314363A2 (en) Anti-anxiety agents
EA011635B1 (ru) Новые производные амида гетероциклической карбоновой кислоты
JPH05213751A (ja) 一連のアレコロンおよびイソアレコロンのニコチン様活性
TWI332499B (en) Chemical compounds
JP2002532472A (ja) ５−ｈｔ１ａ受容体活性を有するアリールピペリジンおよびアリール−１，２，５，６−テトラヒドロピリジン尿素誘導体
JP2006298939A (ja) ニューロキニンアンタゴニストとしての置換オキシムおよびヒドラゾン
JPH111472A (ja) ベンズアミド誘導体及びそれを含有する医薬組成物
CA2172163A1 (en) Imidazolidinone derivative, acid-addition salt thereof, and remedy for senile dementia
JPH1171350A (ja) ヒドロキシピペリジン化合物およびその剤